Market revenue in 2023 | USD 13,226.3 million |
Market revenue in 2030 | USD 28,455.6 million |
Growth rate | 11.6% (CAGR from 2023 to 2030) |
Largest segment | Personalized nutrition & wellness |
Fastest growing segment | PM Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | PM Diagnostics, PM Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Illumina Inc, Asure Software Inc, Abbott Laboratories, Danaos Corp, Exact Sciences Corp, Danaher Corp, Amgen Inc, Qiagen NV, Exagen Inc Ordinary Shares, Quest Diagnostics Inc, Biogen Inc, Genelux Corp, International Business Machines Corp, Genentech, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to personalized medicine market will help companies and investors design strategic landscapes.
Personalized nutrition & wellness was the largest segment with a revenue share of 33.28% in 2023. Horizon Databook has segmented the South Korea personalized medicine market based on pm diagnostics, pm therapeutics, personalized medical care, personalized nutrition & wellness covering the revenue growth of each sub-segment from 2018 to 2030.
Genomic medicine is a rapidly growing industry in South Korea, with much popularity gained by genetic testing, genomic research, and precision medicine. In addition, policymakers are increasingly focusing on DTC genetic tests & services, which is anticipated to encourage the entry of emerging companies into the market.
Furthermore, the Asan Medical Center (AMC) Cancer Institute, based in Seoul, is South Korea’s largest cancer treatment center. It closely works with international organizations to enhance the country's position in precision cancer care. The ASAN Center for Cancer Genome Discovery (ASAN-CCGD) was established as a part of an agreement between the AMC Institute and the Dana-Farber Cancer Institute.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea personalized medicine market , including forecasts for subscribers. This country databook contains high-level insights into South Korea personalized medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account